Concepedia

Author

MO Karlsson

Uppsala University

Also Known As

M Karlsson, M. KARLSSON, M.-B. KARLSSON, MO Karlsson

33

Publications

1.5K

Citations

18

H-Index

71

Concepts

All Affiliations

Uppsala UniversityPfizer (United States)Novo Nordisk (Denmark)AstraZeneca (Sweden)
MK

About

MO Karlsson is an author at Uppsala University specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

917

2

Health Sciences

2

2

81

3

Engineering

1

1

640

4

Public Health

1

1

13

5

Social Sciences

1

1

26

MO Karlsson

×

22

Publications

1.5K

Citations

18

H-Index

YearCitations

Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

RJ Keizer, MO Karlsson, Andrew C. Hooker

CPT Pharmacometrics & Systems Pharmacology

2013

640

Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin

M-L Dahl, Jonas Cederberg, MO Karlsson,

Clinical Pharmacology & Therapeutics

2007

94

Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug‐Resistant Tuberculosis: The Effect of Time‐Varying Weight and Albumin

EM Svensson, A‐G Dosne, MO Karlsson

CPT Pharmacometrics & Systems Pharmacology

2016

80

Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.

Moustapha Hassan, Anders Fasth, B Gerritsen,

PubMed

1996

76

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

Marie Sandström, MO Karlsson, Per Ljungman,

Bone Marrow Transplantation

2001

69

Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment

Bengt Hamrén, Erik Björk, Maria Sunzel,

Clinical Pharmacology & Therapeutics

2008

66

Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements

AJ Ten Tije, MA Carducci, Jil Weber,

Clinical Pharmacology & Therapeutics

2008

54

Comparisons of Analysis Methods for Proof‐of‐Concept Trials

KE Karlsson, Camille Vong, Martin Bergstrand,

CPT Pharmacometrics & Systems Pharmacology

2013

52

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib‐Treated Patients With GIST

EK Hansson, Guo Ma, MA Amantea,

CPT Pharmacometrics & Systems Pharmacology

2013

46

Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model‐Based Drug Development

Lutz Harnisch, Ivan Matthews, J Chard,

CPT Pharmacometrics & Systems Pharmacology

2013

44

Page 1